Middle East & Africa Ultomiris Drug Market Size & Outlook
Related Markets
MEA ultomiris drug market highlights
- The MEA ultomiris drug market generated a revenue of USD 100.7 million in 2024.
- The market is expected to grow at a CAGR of 29.2% from 2025 to 2030.
- In terms of segment, paroxysmal nocturnal hemoglobinuria (pnh) was the largest revenue generating indication in 2024.
- Paroxysmal Nocturnal Hemoglobinuria (PNH) is the most lucrative indication segment registering the fastest growth during the forecast period.
MEA data book summary
| Market revenue in 2024 | USD 100.7 million |
| Market revenue in 2030 | USD 478.0 million |
| Growth rate | 29.2% (CAGR from 2025 to 2030) |
| Largest segment | Paroxysmal nocturnal hemoglobinuria (pnh) |
| Fastest growing segment | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Historical data covered | 2019 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Key market players worldwide | AstraZeneca PLC |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.6% of the global ultomiris drug market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Latin America is the fastest growing regional market and is projected to reach USD 1,163.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ultomiris Drug Market Scope
Ultomiris Drug Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
Middle East & Africa ultomiris drug market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ultomiris drug market will help companies and investors design strategic landscapes.
Paroxysmal nocturnal hemoglobinuria (pnh) was the largest segment with a revenue share of 132.08% in 2024. Horizon Databook has segmented the Middle East & Africa ultomiris drug market based on paroxysmal nocturnal hemoglobinuria (pnh) covering the revenue growth of each sub-segment from 2019 to 2030.
MEA region growing focus on rare diseases and improving healthcare infrastructure support the Ultomiris market. Enhancing diagnostic capabilities enables earlier detection of conditions like PNH and aHUS. Healthcare professionals' increasing awareness of complement inhibitors facilitates the drug's adoption.
Collaborations and partnerships within the healthcare sector contribute to market development. Educational initiatives raise awareness among patients and providers about treatment options. These factors collectively drive the growth of Ultomiris in the MEA region.
Reasons to subscribe to Middle East & Africa ultomiris drug market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa ultomiris drug market databook
-
Our clientele includes a mix of ultomiris drug market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa ultomiris drug market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa ultomiris drug market from 2019 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Middle East & Africa Ultomiris Drug Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
